Moderator notice: Please do not ask for medical advice in this forum!
- If you are interested in Crafting, maybe try ordering a craft kit online (something substantial that would take time would be best, like a Latch hook kit (and crochet hook if you don’t have one), a potholder loom and cotton loops, or cross stitch kit), to work on.
- learn something physical, like an instrument, how to sew or knit, etc
- a lot of museums and zoos and the like are doing virtual tours or free online classes, so keep an eye out for that as well.
- do a giant puzzle
- Join an online bookclub
- Take an online class
While the outbreak started around New Year's Day (12/31), it's picking up steam around the Asia-Pacific region especially since Mainland Chinese people tend to travel a lot.
For reference, the BNO Newsroom twitter has a special feed for any info on the coronavirus:
https://twitter.com/bnodesk?lang=en
The WHO has page about COVID-19 and any other concerns people may have. I suggest peeps go to the Q&A page to check for official details.
https://www.who.int/emergencies/diseases/novel-coronavirus-2019
Edited by nombretomado on Jun 3rd 2020 at 3:21:48 AM
So if the FDA has already halted the J&J vaccine then how likely would it be that it gets permanently taken off shelves?
They may simply want more data before reauthorising it for some use. I’d be surprised if it goes totally unused.
“And the Bunny nails it!” ~ Gabrael “If the UN can get through a day without everyone strangling everyone else so can we.” ~ CyranI was able to contact the pharmacy and according them it's only a recommendation right now but they're waiting for the CDC to release an official statement tomorrow but still continuing while screening women with preexisting blood clot issues. They'll call me if my appointment is cancelled but if I don't hear anything then it'll proceed as normal.
1 Moderna down, 1 to go. Just killing time waiting for side-effects.
My mom got the vaccine (Pfizer or Moderna, not sure which) and hasn’t had any side effects.
Won’t be getting the second dose for a long while, but given that studies are indicating 80% protection from the first dose rising to 90% with the second, the first one is by far the most important.
My dad’s scheduled for his first dose before the end of the month, and my aunt is getting Astro-Zeneca.
I’m in my 30s, work from home, and am not in a high-risk district, so I’m unlikely to get one before August, but it’s nice that the rollout has sped up a good bit from where we were in February.
Edited by Galadriel on Apr 13th 2021 at 7:56:14 AM
We were only able to get our because Cook County (possibly Illinois as a whole) went from having restrictions on who can get the vaccine to a free-for-all. Great for everyone that's been waiting, but I feel bad for anyone at risk that now has to compete with the general population.
No side effects of note so far. If anything I feel better than I have in awhile.
Plus I got a sticker!
Side effects in the waiting room seem to be pretty uncommon and/or mostly minor/psychosomatic. It's the next day that's really noticeable, and it's like getting a bad cold/mild flu for a day. Arms tend to stay sore longer, probably because they're actually (mildly) damaged.
Can second that. My arm only really started aching last night, hours after actually getting the shot. Also, my parents got their second dose today and have reported no noticeable side effects, but my dad says he's expecting them tomorrow.
Same. No other side effects, but my arm started aching last night and only let up a few hours ago.
According to a CNN article I found, the biggest reason why it was temporarily halted is because less because of the fact that it could cause blood clots, and more because the type of clots seen, need to be treated differently than other types.
"The issue here with these types of blood clots is that if one administers the standard treatment that we as doctors have learned to give for blood clots, one can cause tremendous harm," Marks said in Tuesday's briefing.
The rare type of blood clots observed in association with the vaccine require unique treatment. For instance, the anticoagulant drug heparin should not be used to treat these types of blood clots, Marks said, adding that health care providers had to be made aware of the pause immediately in case they see patients with possible blood clot symptoms.
"Treatment for this specific type of blood clot is different from typical treatments for other types of blood clots, which usually involve an anticoagulant called heparin," he said. "With cerebral venous sinus thrombosis, heparin may be dangerous and alternative treatments need to be given, preferably under the guidance of physicians experienced in the treatment of blood clots."
Edited by megaeliz on Apr 13th 2021 at 12:15:25 PM
I just heard from Colbert that it's something to the tune of 6 cases out of, what, 6 million doses administered?
I understand the need for caution, believe me. My wife's PE was terrifying. But is the slowdown in vaccination when a 4th wave could be building worth it?
You're more likely to get struck by lightning than to get a blood clot from this vaccine.
Seriously, according to the CDC the odds of being struck by lightning are about 1 in 500,000.
Disgusted, but not surprisedit’s actually more common than you’d think for rare side effects not to show up in the studies and clinical trials, simply because, statistically, you just don’t have enough people for it to even be a meaningful probability.
"But I want to congratulate the CDC and the FDA for very quickly jumping on it, halting the vaccinations until we know more, and really trying to understand what's going on," del Rio said. "I think vaccine safety has always been a priority — and I think this is exactly the right move until we understand what's going on and what's the way forward."
It’s also worth noting that even the FDA Commissioner only thinks this will be a momentary setback.
"As we learned about the issue with appropriate treatment, it was clear to us that we needed to alert the public," Woodcock said.
"The timeframe will depend obviously on what we learn in the next few days," Woodcock said. "However, we expect it to be a matter of days for this pause."
Edited by megaeliz on Apr 14th 2021 at 5:32:46 AM
Let's hope they're not just covering their asses.
@Chris: I'm also in Cook County.
I like to keep my audience riveted.I belive the concern is that the 6 million haven’t all had the vaccine long enough to potentially develop the side effects and that the side effects are focused around a specific demographic group (younger women). So they need a bit of time to work out if there might be a relatively high risk for younger people, women, or younger women receiving it.
It’s the same reason the UK sis currently holding off giving Astra Zenica to people under 30. Though that doesn’t disrupt our program much as unless you’re in a priority category (healthcare worker, underlying conditions, home carer, ect...) under 45s can’t currently get vaccinated here.
“And the Bunny nails it!” ~ Gabrael “If the UN can get through a day without everyone strangling everyone else so can we.” ~ CyranIt’s still going to be very rare regardless. Remember, we saw no cases in the clinical trial phases, despite the very large sample size, which speaks to its rarity. (This also occasionally happens in studies with much smaller sample size as well.)
Edited by megaeliz on Apr 13th 2021 at 2:15:50 PM
Did the clinical trials include enough young women? Some other clinical trials do not include women who may become pregnant, and I was wondering if that was the case for the COVID-19 vaccines as well.
"Enshittification truly is how platforms die"-Cory DoctorowThey probably did, at least with Astra Zenica even amongst younger women it’s a rare side effect. You’d probably need to include hundreds of thousands of younger women to notice, when trials will normally have tens of thousands total.
Edited by Silasw on Apr 13th 2021 at 7:44:01 PM
“And the Bunny nails it!” ~ Gabrael “If the UN can get through a day without everyone strangling everyone else so can we.” ~ CyranAustralian government, voting to block vaccine IP waivers at the WTO: Hahahaha!! Yes!!!!
Australian government, not getting enough vaccine doses from suppliers: Wow this sucks.
The country has only been able to vaccinate just over 4 million people and is not expected to hit its target of 130 million until the middle of 2023.
All of its doses are being manufactured in neighbouring India.
But the country's drug makers say they could produce hundreds of millions of doses in a quick timeframe, if only they could secure a vaccine blueprint.
"I think the world cannot wait so long to be vaccinated," the chairman of Incepta Pharmaceuticals, Abdul Muktadir, said.
"If we make these vaccines readily available, in [plentiful] numbers, then automatically this problem is going to be solved."
Incepta Pharmaceuticals lies on the outskirts of the Bangladesh capital Dhaka, in an industrial neighbourhood.
Fitted out with the latest technology from Germany, the company already produces vaccines to fight a wide array of diseases such as hepatitis b, typhoid, the flu, tetanus, measles, meningococcal and rabies.
Mr Muktadir said the company had plenty of capacity to produce more drugs and could manufacture between 600 to 800 million doses of COVID-19 vaccines annually.
"If we get the ready-to-fill material or antigen, instead of waiting until 2023, we can make this vaccine available to our entire nation population within two to three months' time," he said.
"Then Indonesia or any other nation where authorities want to take the vaccination from us, we can give it to them within 2021."
Why an idea for free vaccine licences was rejected
Currently, pharmaceutical companies that invent the vaccines have control over who is issued a licence to produce it.
India and South Africa, supported by developing countries and international aid groups, unsuccessfully led a charge to have a temporary waiver on intellectual property rights, so a third party could distribute licences to produce COVID-19 vaccines.
A similar waiver was made two decades ago to help produce generic drugs during the HIV/AIDS epidemic.
Advocates say the move would help ensure low-income countries do not experience surges as they endure long waits for vaccines, like that being witnessed in Papua New Guinea.
But the move failed after wealthy countries, including Australia, blocked the proposal in the World Trade Organisation.
Harsh Pant, the director of strategic studies at the Observer Research Foundation in Delhi, said pharmaceutical companies want to ensure they can secure a profit, after spending large sums of money and resources into developing the vaccine.
Proponents of the current system argue it is needed to fuel innovation.
"You pour a huge amount of money and research and you reap the benefits," Mr Pant said.
Pharmaceutical companies also want to ensure the final product meets their stringent standards and that the unique recipe is protected from being leaked onto the black market.
But Mr Pant said the tight controls on COVID-19 vaccine licences, which have created a supply shortage, were not justified considering the damage the pandemic had caused.
"It's a do or die situation," Mr Pant said.
"It's life and death. So, I think the position by India and South Africa is an important one and it goes to the heart of global governance where equity is a concern."
He also criticised wealthy nations for using their purchasing power to buy up most of the vaccines, forcing developing nations to scramble for a limited supply.
"Almost 80 per cent of vaccines are going to 10 or 12 countries," he said.
"It has been about vaccine nationalism, hoarding a vaccine. You'd expect them to be a bit more generous."
Why current measures might not be enough
The so-called 'Quad nations' of India, Australia, Japan and the United States announced an extra billion vaccines would be distributed throughout the Indo Pacific region before the end of 2023.
The deal would utilise India's massive vaccine making capabilities, with Hyderabad pharmaceutical company Biological E to produce the doses, including one vaccine developed by Johnson & Johnson.
Public health expert Rajib Dasgupta from Delhi's Jawaharlal Nehru University said the extra vaccines were not "a very remarkably big chunk", but would help recipient countries better target at-risk communities or respond to local surges.
"It will boil down to which segment of the population a country will prioritise to protect," he said.
"It's not a one-time decision, it's an evolving decision."
India is aiming to inoculate 300 million people by August. Its program is aimed at supporting those most at risk — like the elderly or healthcare workers — and not about achieving herd immunity.
Yet the country is already behind schedule and at least two states, Kerala and Rajasthan, have complained about a shortage of vaccine supply, something India's government has denied.
The Serum Institute, which has licences to produce the Oxford-AstraZeneca vaccine and Novavax, has already flagged a shortage of some items for vaccine production after five million doses were delayed for the UK.
Biological E has also flagged potential delays.
India has domestic laws that allow it to compulsorily acquire intellectual property rights for the manufacturing and distribution of drugs.
Dr Dasgupta said if this was invoked, India could not only rapidly ramp up vaccine supplies to better vaccinate its country, but allow more pharmacies to distribute the vaccine.
"This is going to be an extremely crucial tool," he said.
"The opening up of the IP is the first step to an assured large quantum of supply. There's no point being liberal with the distribution network without ensuring supply."
The World Health Organisation's COVAX program is also hoping this year to distribute 2 billion doses of vaccine to at least 92 low-income countries.
But that, according to its own estimates, would only reach about a fifth of the target populations.
The Quad, which is not a military alliance, is widely seen as a response to an increasingly assertive China, which is also producing large quantities of vaccines for the region.
Abhijnan Rej, the security & defence editor at The Diplomat, said the Quad deal was not about pushing Chinese vaccines out of the Indo-Pacific, but rather giving countries an "alternative" or choice.
"China is not the only game in town," he said.
"I think that is really the larger geopolitical message."
I got my first shot of the Pfizer vaccine yesterday.
So far, I didn’t feel anything other than a sore arm.
For the J&J vaccine, there also seems to be a concern about lawsuit-happy Americans.
Optimism is a duty.A South Korean dairy company's stocks went up by 30% in one day because one of their scientists said that their yogurt kills the flu virus and the COVID-19 virus in monkey lung cells. Of course, these results mean jack shit, and when Korea's FDA and the Disease Control Agency issued statements to that effect, their stock prices went back down. I guess some of their investors learned a very expensive lesson on how science is supposed to work.
"Enshittification truly is how platforms die"-Cory DoctorowWhile other investors learned a valuable lesson on how telling bold lies can make you a quick 130% profit.
Vaccination doesn't seem to be going well at all in the Netherlands. And we can't even blame some right wing autocrat, either.
Optimism is a duty.